Overview

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Status:
Active, not recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborators:

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Medivation, Inc.

Treatments:

Androgens
Ascorbic Acid
Estrogens, Conjugated (USP)
Hormones
Methyltestosterone
Prolactin Release-Inhibiting Factors